These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 32717289)

  • 1. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
    J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
    J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatobiliary transport kinetics of the conjugated bile acid tracer
    Ørntoft NW; Munk OL; Frisch K; Ott P; Keiding S; Sørensen M
    J Hepatol; 2017 Aug; 67(2):321-327. PubMed ID: 28249726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
    Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
    Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
    Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
    Kowdley KV; Luketic V; Chapman R; Hirschfield GM; Poupon R; Schramm C; Vincent C; Rust C; Parés A; Mason A; Marschall HU; Shapiro D; Adorini L; Sciacca C; Beecher-Jones T; Böhm O; Pencek R; Jones D;
    Hepatology; 2018 May; 67(5):1890-1902. PubMed ID: 29023915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obeticholic acid in primary biliary cholangitis: where we stand.
    Manne V; Kowdley KV
    Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic bile acid transport increases in the postprandial state: A functional
    Ørntoft NW; Gormsen LC; Keiding S; Munk OL; Ott P; Sørensen M
    JHEP Rep; 2021 Jun; 3(3):100288. PubMed ID: 34095797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis.
    Akepati PR; Gochanour EM
    Expert Opin Investig Drugs; 2024 Jun; 33(6):627-638. PubMed ID: 38676426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
    Nevens F; Andreone P; Mazzella G; Strasser SI; Bowlus C; Invernizzi P; Drenth JP; Pockros PJ; Regula J; Beuers U; Trauner M; Jones DE; Floreani A; Hohenester S; Luketic V; Shiffman M; van Erpecum KJ; Vargas V; Vincent C; Hirschfield GM; Shah H; Hansen B; Lindor KD; Marschall HU; Kowdley KV; Hooshmand-Rad R; Marmon T; Sheeron S; Pencek R; MacConell L; Pruzanski M; Shapiro D;
    N Engl J Med; 2016 Aug; 375(7):631-43. PubMed ID: 27532829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obeticholic acid for the treatment of primary biliary cirrhosis.
    Trivedi PJ; Hirschfield GM; Gershwin ME
    Expert Rev Clin Pharmacol; 2016; 9(1):13-26. PubMed ID: 26549695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
    J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
    Guo C; LaCerte C; Edwards JE; Brouwer KR; Brouwer KLR
    J Pharmacol Exp Ther; 2018 May; 365(2):413-421. PubMed ID: 29487110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
    Silveira MG; Lindor KD
    Expert Opin Pharmacother; 2014 Feb; 15(3):365-72. PubMed ID: 24382005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.